ArticleNeuro-oncology advances
Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexamethasone (DEX) is routinely administered perioperatively to manage tumor-associated vasogenic edema in glioblastoma (GBM), yet increasing evidence suggests that corticosteroid exposure may adversely affect survival. The magnitude of this association during the initial neurosurgical phase of care remains unclear. Methods: We performed a retrospective cohort study of patients with histologically confirmed IDH-wildtype GBM treated at a single tertiary center between 2009 and 2020. All perioperative DEX doses from admission to discharge were extracted from daily medical records. Patients were stratified based on the cumulative dose into low-dose exposure (<34 mg) and high-dose exposure (≥34 mg) groups using maximally selected rank statistics. Overall survival was analyzed using Kaplan-Meier estimates with log-rank test and multivariable Cox proportional hazards models. Adjustment variables were selected using a prespecified, causally informed framework to address confounding. Results: A total of 420 patients were included. The majority ( Conclusions: Higher perioperative DEX doses were independently associated with shorter overall survival in GBM patients, emphasizing the need for judicious perioperative use with prompt tapering. Prospective studies are warranted to guide evidence-based DEX management in GBM care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.